Biotech R&D · global
Genome & Company Joins Lilly’s TuneLab to Screen Antibody and Small-Molecule Drug Candidates with AI
From finding new targets to selecting molecules worth testing, a lengthy screening process remains. South Korea’s Genome & Company plans to connect its proprietary target discovery platform with Lilly’s predictive models to support preclinical development and technology transfer; potential time and cost savings have yet to be publicly validated.
Finding a new target that may be associated with disease is only the starting point for drug development. Research teams must then determine which of many molecules merit the next round of experiments. South Korean biotech company Genome & Company announced on October 20 that it had joined Eli Lilly’s AI drug discovery platform, TuneLab, with plans to use predictive models at this screening stage.
Money Today and Korea Economic TV reported that the company will combine its proprietary GNOCLE platform with TuneLab: the former uses genomic analysis and clinical data to identify new targets, while the latter predicts the properties of antibodies and small-molecule compounds to help evaluate drug candidates developed against those targets. The company hopes this will allow it to prioritize more promising molecules and reduce experiments involving candidates with lower chances of success.
The arrangement has a clear R&D context. The company’s pipeline listed in the reports includes GENA-104 ADC, which targets CNTN4; GENA-120, which targets ITGB4; and GENB-120, which targets both ITGB4 and TROP2, as well as GENC-116, a small molecule that inhibits NUAK1 kinase. However, the available reports do not specify which programs will adopt TuneLab first or disclose evaluation metrics for the individual predictions.
The conditions for participation also affect small biotech companies’ business strategies. According to Money Today, companies can join TuneLab only after Lilly reviews their suitability, while rights to R&D results obtained through the platform belong to the participating companies. ChosunBiz quoted Genome & Company’s general representative, Hong Yoo-seok, as saying that assessing drug candidates’ development potential earlier would help advance the company’s preclinical technology transfer strategy. Joining the platform does not itself constitute evidence of a completed drug licensing deal.
Currently, publicly available information remains focused on implementation plans. The reports cited above provide no data on model accuracy for Genome & Company’s drug candidates, prospective experimental results, or actual reductions in development timelines and costs; nor do they detail the size and composition of the clinical data used by GNOCLE. Efficiency improvements therefore remain a goal the company hopes to achieve and cannot yet be regarded as validated results.
Background
TuneLab represents a model in which a large pharmaceutical company makes predictive tools available to external R&D teams. The specific development here is Genome & Company’s plan to connect these tools to its proprietary target discovery process, allowing AI to help select candidate molecules. For research teams, the practical value will depend on whether the models can provide information that improves experimental decisions across unfamiliar targets and different types of molecules.
The key next step is whether the predictions withstand experimental testing. Even if the models help prioritize research, drug candidates’ activity, toxicity, and performance in vivo still require step-by-step confirmation. To support technology transfer, Genome & Company will also need to translate model assessments into experimental evidence that potential partners can review.